KIAA1199 further reduces the expression of Sema3A, increases the expression of VE-cadherin and phosphorylated EphA2, and enhances angiogenesis and vasculogenic mimicry in prostate cancer by enhancing hyaluronic acid-mediated VEGFA signaling (49). The gene discussed is EPHA2; the disease is prostate cancer.